| Name | Advance Pharmacy |
|---|---|
| Organization Name | Bsap Llc |
| Location | 110 S Oak St, Advance, Missouri 63730 |
| Type | Pharmacy |
| Phone | (573) 722-3562 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Golden Valley Development, Inc. is pleased to announce the development of the PERCUGUARD needlestick prevention device, a tool currently unavailable in the medical and dental industries, exceeding 1 billion potential annual applications worldwide.
"Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse," said Brookhaven neuroanatomist Stephen Dewey, who led the research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing."
People living in the Seveso area of Italy, which was exposed to dioxin after an industrial accident in 1976, have experienced an increased risk of developing cancer. Researchers writing in BioMed Central's open access journal Environmental Health found an increased risk of breast cancer in women from the most exposed zone and an excess of lymphatic and hematopoietic tissue neoplasms in all but the least exposed zone.
Findings from a study conducted in the UK support the country's decision to extend the dosing interval of coronavirus disease 2019 (COVID-19) vaccination from 3 weeks to 12 weeks in order to prioritize the first dose for those at high risk of severe disease and death.
› Verified 8 days ago
| NPI Number | 1033150891 |
| Organization Name | BSAP LLC |
| Doing Business As | ADVANCE PHARMACY |
| Type | Pharmacy |
| Address | 110 S Oak St, Advance, MO 63730 |
| Phone Number | 573-722-3562 |
News Archive
Golden Valley Development, Inc. is pleased to announce the development of the PERCUGUARD needlestick prevention device, a tool currently unavailable in the medical and dental industries, exceeding 1 billion potential annual applications worldwide.
"Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse," said Brookhaven neuroanatomist Stephen Dewey, who led the research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing."
People living in the Seveso area of Italy, which was exposed to dioxin after an industrial accident in 1976, have experienced an increased risk of developing cancer. Researchers writing in BioMed Central's open access journal Environmental Health found an increased risk of breast cancer in women from the most exposed zone and an excess of lymphatic and hematopoietic tissue neoplasms in all but the least exposed zone.
Findings from a study conducted in the UK support the country's decision to extend the dosing interval of coronavirus disease 2019 (COVID-19) vaccination from 3 weeks to 12 weeks in order to prioritize the first dose for those at high risk of severe disease and death.
› Verified 8 days ago
News Archive
Golden Valley Development, Inc. is pleased to announce the development of the PERCUGUARD needlestick prevention device, a tool currently unavailable in the medical and dental industries, exceeding 1 billion potential annual applications worldwide.
"Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse," said Brookhaven neuroanatomist Stephen Dewey, who led the research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing."
People living in the Seveso area of Italy, which was exposed to dioxin after an industrial accident in 1976, have experienced an increased risk of developing cancer. Researchers writing in BioMed Central's open access journal Environmental Health found an increased risk of breast cancer in women from the most exposed zone and an excess of lymphatic and hematopoietic tissue neoplasms in all but the least exposed zone.
Findings from a study conducted in the UK support the country's decision to extend the dosing interval of coronavirus disease 2019 (COVID-19) vaccination from 3 weeks to 12 weeks in order to prioritize the first dose for those at high risk of severe disease and death.
› Verified 8 days ago